Short- and long-term effects of cytochalasin D, paclitaxel and rapamycin on wall thickening in experimental porcine vein grafts

Cardiovascular Research

Volumn 73, Issue 3, 2007, Pages 607-617

  Murphy, Gavin J ^a   Johnson, Thomas W ^a   Chamberlain, Martin H ^a   Rizvi, S Imran ^a   Wyatt, Marcie ^a   George, Sarah J ^a   Angelini, Gianni D ^a   Karsch, Karl R ^a   Oberhoff, Martin ^a   Newby, Andrew C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Neointima; Paclitaxel; Rapamycin; Vein grafts

Indexed keywords

CYTOCHALASIN D; PACLITAXEL; RAPAMYCIN;

ANIMAL TISSUE; ARTICLE; CAROTID ARTERY; CELL LOSS; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIUM; EX VIVO STUDY; HEART GRAFT; INTIMA; KINETICS; NONHUMAN; PRIORITY JOURNAL; SAPHENOUS VEIN; VEIN GRAFT;

ANIMALS; ANTIBIOTIC PROPHYLAXIS; BIOLOGICAL MARKERS; CELL PROLIFERATION; CYTOCHALASIN D; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, ANIMAL; ORGAN CULTURE TECHNIQUES; PACLITAXEL; PROLIFERATING CELL NUCLEAR ANTIGEN; SAPHENOUS VEIN; SIROLIMUS; STAINING AND LABELING; SWINE; TIME; TUNICA INTIMA;

EID: 33846260070     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.11.015     Document Type: Article

References (38)

1. PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. J Am Med Assoc 294 (2005) 2446-2454
2. Widimsky P., Straka Z., Stros P., Jirasek K., Dvorak J., Votava J., et al. One-year coronary bypass graft patency: a randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 trial. Circulation 110 (2004) 3418-3423
3. Motwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97 (1998) 916-931
4. Goldman S., Copeland J., Moritz T., Henderson W., Zadina K., Ovitt T., et al. Long-term graft patency (3 years) after coronary-artery surgery effects of aspirin - results of a Va Cooperative Study. Circulation 89 (1994) 1138-1143
5. Investigators TPCABGT. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation of obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336 (1997) 153-162
6. Angelini G.D., Izzat M.B., and Newby A.C. External stenting reduces early medial and intimal thickening in a pig model of arteriovenous bypass grafting. J Thorac Cardiovasc Surg 112 (1996) 79-84
7. Izzat M.B., Mehta D., Bryan A.J., Reeves B., Newby A.C., and Angelini G.D. The influence of external stent size on early medial and neointimal thickening in a pig model of saphenous vein bypass grafting. Circulation 94 (1996) 1741-1745
8. Mehta D., George S.J., Jeremy J.Y., Izzat M.B., Southgate K.M., Bryan A.J., et al. External stenting reduces long term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting. Nat Med 4 (1998) 235-239
9. Angelini G.D., Lloyd C., Bush R., Johnson J., and Newby A.C. An external, oversized, porous polyester stent reduces vein graft neointima formation, cholesterol concentration, and vascular cell adhesion molecule 1 expression in cholesterol-fed pigs. J Thorac Cardiovasc Surg 124 (2002) 950-956
10. Mann M.J., Gibbons G.H., Kernoff R.S., Diet F.P., Tsao P.S., Cooke J.P., et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A 92 (1995) 4502-4506
11. Ehsan A., Mann M.J., Dell'Acqua G., and Dzau V.J. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 121 (2001) 714-722
12. Mann M.J., Whittemorre A.D., Donaldson M.C., Belkin M., Conte M.S., Polak J.F., et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy; the prevent single centre randomised controlled trial. Lancet 354 (1999) 1493-1498
13. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
14. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
15. Aoki J., Colombo A., Dudek D., Banning A.P., Drzewiecki J., Zmudka K., et al. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: Insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 112 (2005) 3876-3883
16. Sousa J.E., Costa M.A., Abizaid A., Feres F., Seixas A.C., Tanajura L.F., et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 111 (2005) 2326-2329
17. Marx S.O., and Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104 (2001) 852-855
18. Cooper J.A. Effects of cytochalasin and phalloidin on actin. J Cell Biol 105 (1987) 1473-1478
19. Axel D.I., Kunert W., Goggelmann C., Oberhoff M., Herdeg C., Kuttner A., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 (1997) 636-645
20. White S.J., and Newby A.C. Gene therapy for all aspects of vein graft disease. J Card Surg 17 (2002) 549-555
21. Angelini G.D., Bryan A.J., Williams H.M.J., Soyombo A.A., Williams A., Tovey J., et al. Timecourse of medial and intimal thickening in pig arteriovenous bypass grafts: relationship to endothelial injury and cholesterol accumulation. J Thorac Cardiovasc Surg 103 (1992) 1093-1103
22. Higuchi Y., Hirayama A., Shimizu M., Sakakibara T., and Kodama K. Postoperative changes in angiographically normal saphenous vein coronary bypass grafts using intravascular ultrasound. Heart Vessels (2002) 57-60
23. Soyombo A.A., Angelini G.D., Bryan A.J., Jasani B., and Newby A.C. Intimal proliferation in an organ culture of human saphenous vein. Am J Pathol 137 (1990) 1401-1410
24. Angelini G.D., Bryan A.J., Williams H.M.J., Morgan R., and Newby A.C. Distention promotes platelet and leukocyte adhesion and reduces short-term patency in pig arteriovenous bypass grafts. J Thorac Cardiovasc Surg 99 (1990) 433-439
25. George S.J., Zaltsman A.B., and Newby A.C. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res 33 (1997) 447-459
26. George S.J., Baker A.H., Angelini G.D., and Newby A.C. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 5 (1998) 1552-1560
27. George S.J., Izzat M.B., Gadsdon P., Johnson J.L., Yim A.P.C., Wan S., et al. Macroporosity is necessary for the reduction of neointimal and medial thickening by external stenting of porcine saphenous vein bypass grafts. Atherosclerosis 155 (2001) 329-336
28. Bruijns R.H.J., and Bult H. Effects of local cytochalasin D delivery on smooth muscle cell migration and on collar-induced intimal hyperplasia in the rabbit carotid artery. Br J Pharmacol 134 (2001) 473-483
29. Schachner T., Zou Y., Oberhuber A., Tzankov A., Mairinger T., Laufer G., et al. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg 77 (2004) 1580-1585
30. Creel C.J., Lovich M.A., and Edelman E.R. Arterial paclitaxel distribution and deposition. Circ Res 86 (2000) 879-884
31. Salu K.J., Bosmans J.M., Huang Y.M., Hendriks M., Verhoeven M., Levels A., et al. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model. Cardiovasc Res 69 (2006) 536-544
32. Kim S.J., Masaki T., Leypoldt J.K., Kamerath C.D., Mohammad S.F., and Cheung A.K. Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs. J Lab Clin Med 144 (2004) 156-162
33. Kennedy S., Wadsworth R.M., and Wainwright C.L. Effect of antiproliferative agents on vascular function in normal and in vitro balloon-injured porcine coronary arteries. Eur J Pharmacol 481 (2003) 101-107
34. Heldman A.W., Cheng L., Jenkins G.M., Heller P.F., Kim D.W., Ware M., et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103 (2001) 2289-2295
35. Zou Y., Dietrich H., Hu Y., Metzler B., Wick G., and Xu Q. Mouse model of vein bypass graft arteriosclerosis. Am J Pathol 153 (1998) 1301-1310
36. Masaki T., Rathi R., Zentner G., Leypoldt J.K., Mohammad S.F., Burns G.L., et al. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int 66 (2004) 2061-2069
37. Vijayan V., Shukla N., Johnson J.L., Gadsdon P., Angelini G.D., Smith F.C.T., et al. Long-term reduction of medial and intimal thickening in porcine saphenous vein grafts with a polyglactin biodegradable external sheath. J Vasc Surg 40 (2004) 1011-1019
38. Kolodgie F.D., John M., Khurana C., Farb A., Wilson P.S., Acampado E., et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 106 (2002) 1195-1198